Collaborative Drug Discovery - Wiley Technologies for the Pharmaceutical Industry by Rathnam Chaguturu Hardcover

Book Synopsis

The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Founder and CEO of iDDPartners, focused on pharmaceutical innovation, Founding president of the International Chemical Biology Society, and Senior Director-Discovery Sciences, SRI International, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.

• Gain global perspectives on the benefits and potential issues surrounding collaborative innovation
• Discover how industries can come together to prevent another "Pharma Cliff"
• Learn how nonprofits are becoming the driving force behind innovation
• Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration
• Explore government initiatives that help foster cooperation between industry and academia

Dr. Chaguturu's thirty-five years of experience in academia and industry, managing new lead discovery projects and forging collaborative partnerships with academia, disease foundations, nonprofits, and government agencies lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.

From the Back Cover

Sets the stage for a new, improved paradigm in drug discovery

Despite spending more than $135 billion annually on R&D, the pharmaceutical industry faces an innovation crisis. Given the complexities and the expense of R&D, this book argues that we can accomplish much more--with greater efficiency and less cost--when private and public sectors collaborate, each focusing on their core strengths.

Collaborative Innovation in Drug Discovery focuses on the early stage of drug discovery, the most critical barrier to delivering a steady flow of viable drug candidates into the pipeline. The book assesses the current state of drug discovery in the pharmaceutical industry, government, non-profit, and academia, identifying the areas where each sector excels and areas where gaps exist. Next, the authors explore ways these sectors can establish mutually beneficial partnerships in order to discover, develop, and bring to market improved, safer drugs to treat human diseases. Topics include:

• Status of healthcare and unmet medical needs
• Biomedical research environment, drug discovery efforts, and market risks in industry and academia
• NIH Roadmap and EU-OpenScreen initiatives
• Trends in academia-pharmaceutical partnerships, including case studies
• Drug repositioning, open source partnerships, and challenges and practices for conducting clinical trials

Editor Rathnam Chaguturu has assembled a panel of expert authors from around the world, representing all the sectors involved in drug discovery. Their contributions are not only based on a thorough review of the current literature, but also their own first-hand experience of what works and what doesn't.

Collaborative Innovation in Drug Discovery offers pharmaceutical scientists and managers working in both private and public sectors a new, more productive road map to discover drugs that the world needs.

About the Author

RATHNAM CHAGUTURU, PHD, is the Founder & CEO of iDDPartners, a nonprofit think-tank focused on pharmaceutical innovation. He has more than thirty years of experience in executing new lead discovery projects and forging discovery partnerships. He is the Founding President of the International Chemical Biology Society and Editor-in-Chief of Combinatorial Chemistry and High Throughput Screening. He serves on several other editorial and scientific advisory boards along with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national and international conferences, passionately advocating the virtues of collaborative partnerships in addressing the pharmaceutical innovation crisis.